Fatal gene-editing trial in China prompts scrutiny of biotech regulatory oversight

A pediatric death during an experimental gene-editing trial has triggered a re-evaluation of China's rapid biotechnology expansion and ethical oversight frameworks. It remains unclear whether the incident reflects systemic regulatory failure or isolated clinical negligence, but the event highlights growing international concerns regarding the pace of Chinese medical innovation.